HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Intravascular large B-cell lymphoma — Clinical Guidelines

Overview

Intravascular large B-cell lymphoma (IVL) is a rare and aggressive form of non-Hodgkin lymphoma characterized by the proliferation of neoplastic lymphoid cells within small blood vessel lumina, leading to multi-organ dysfunction and often rapid clinical deterioration 10 11 13 15.

Diagnosis

Clinical Presentation: Often presents with nonspecific symptoms including fever, neurological deficits, skin lesions, and multi-organ involvement 10 11 13 14 15.

Imaging and Biopsy: Essential for diagnosis; biopsy showing neoplastic cells within vessel lumina is definitive 10 17.

Immunophenotyping: Immunohistochemical staining for leukocyte common antigen (LCA) and cytokeratin can aid in distinguishing from other malignancies 17.

Differential Diagnosis: Requires exclusion of other causes like sepsis, especially in cases mimicking systemic inflammatory response syndrome 16.

Management

First-Line Treatment: Limited specific guidelines; often involves systemic chemotherapy regimens tailored to patient status 1 3.

Second-Line and Beyond: Chimeric antigen receptor (CAR) T-cell therapy recommended for early relapse (within 12 months) 3.

CAR-T Therapy Considerations: Minimize vein-to-vein time (V2Vt) to optimize outcomes 2.

Other Therapies: Platinum-based chemotherapy followed by high-dose chemotherapy with autologous stem cell rescue for late relapse 3.

Emerging Therapies: CD3xCD20 bispecific antibodies and other targeted therapies under investigation 3 5.

Special Populations

Elderly Patients: Management strategies may need adjustment due to higher comorbidities and frailty 1 3.

Comorbidities: Careful consideration of organ function and potential interactions with aggressive treatments 10 15.

Key Recommendations

CAR-T Therapy for Early Relapse: Use CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma within 12 months of first-line therapy (Evidence: Moderate) 3.

Minimize CAR-T Infusion Delays: Reduce vein-to-vein time to improve clinical outcomes in CAR T-cell therapy (Evidence: Moderate) 2.

Multidisciplinary Approach: Employ a comprehensive multidisciplinary strategy for diagnosis and management, emphasizing early biopsy and immunophenotyping (Evidence: Expert opinion) 10 17.

References

1 Sesques P, Manson G, Dubois S, Gros FX, Brisou G, Sarkozy C et al.. Large B-cell lymphoma: The LYSA pragmatic guidelines. European journal of cancer (Oxford, England : 1990) 2026. link 2 Locke FL, Siddiqi T, Jacobson CA, Nikiforow S, Ahmed S, Miklos DB et al.. Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel. Blood advances 2025. link 3 Chaganti S, Fox CP, Maybury BD, Burton C, Barrington SF, Illidge T et al.. Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology Guideline. British journal of haematology 2025. link 4 Jacobson CA, Munoz J, Sun F, Kanters S, Limbrick-Oldfield EH, Spooner C et al.. Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis. Transplantation and cellular therapy 2024. link 5 Bayly-McCredie E, Treisman M, Fiorenza S. Safety and Efficacy of Bispecific Antibodies in Adults with Large B-Cell Lymphomas: A Systematic Review of Clinical Trial Data. International journal of molecular sciences 2024. link 6 Oluwole OO, Neelapu SS, Ray MD, Limbrick-Oldfield EH, Wade SW, Kanters S et al.. Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies. Expert review of anticancer therapy 2024. link 7 Zanelli M, Sanguedolce F, Zizzo M, Ricci S, Bisagni A, Palicelli A et al.. A Diagnostic Approach in Large B-Cell Lymphomas According to the Fifth World Health Organization and International Consensus Classifications and a Practical Algorithm in Routine Practice. International journal of molecular sciences 2024. link 8 Nath K, Tomas AA, Flynn J, Fein JA, Alperovich A, Anagnostou T et al.. Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell Lymphoma. Transplantation and cellular therapy 2022. link 9 King JF, Lam JT. A Practical Approach to Diagnosis of B-Cell Lymphomas With Diffuse Large Cell Morphology. Archives of pathology & laboratory medicine 2020. link 10 Mase H, Ogawa Y, Takeuchi J, Genda Y, Ichiba S, Sakamoto A. Successful Intensive Care Treatment of Severe Lactic Acidosis and Tumor Lysis Syndrome Related to Intravascular Lymphoma. Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 2020. link 11 Szuba A, Koba M, Rzeszutko M, Rzeszutko W, Dziegiel P, Loboda A et al.. Cutaneous angiogenesis in patient with intravascular lymphoma (IVL): A case report. Dermatology online journal 2010. link 12 Aouba A, Diop S, Saadoun D, Trebbia G, Vilde F, Patri B et al.. Severe pulmonary arterial hypertension as initial manifestation of intravascular lymphoma: case report. American journal of hematology 2005. link 13 Weisel KC, Brugger W, Kröber SM, Kaiserling E, Kanz L. Intravascular lymphoma - a rare cause of hemolytic anemia and neurologic disorders. The hematology journal : the official journal of the European Haematology Association 2004. link 14 Fozza C, Bonfigli S, Conti M, Dore F, Longinotti M. Long-lasting fever of unknown origin preceding the diagnosis of intravascular lymphomatosis: a further case stimulates some remarks. American journal of hematology 2003. link 15 Yanagihori H, Oyama N, Kawakami Y, Sakuma-Oyama Y, Nakamura K, Iwatsuki K et al.. A case of intravascular large B-cell lymphoma with multiple organ involvement. The Journal of dermatology 2003. link 16 Deusch E, Mayr A, Hobisch-Hagen P, Fend F, Mutz N, Bangerl I et al.. Angiotropic large B-cell lymphoma misdiagnosed as urosepsis with multiple organ dysfunction syndrome. Acta anaesthesiologica Scandinavica 1999. link 17 Dean PJ, Moinuddin SM, Emerson LD. Application of anti-leukocyte common antigen and anti-cytokeratin antibodies to the biopsy diagnosis of gastric large cell lymphoma. Human pathology 1987. link80269-1)

Intravascular large B-cell lymphoma